Method for performing coagulation assays accurately, rapidly and simply, using dry chemical reagents and paramagnetic particles

• US 5,110,727 A
• Filed: 05/10/1988
• Issued: 05/05/1992
• Est. Priority Date: 04/03/1987
• Status: Expired due to Term

• Current Assignee: Cardiovascular Diagnostics, Inc. (PharmaNetics, Inc.)
• Original Assignee: Cardiovascular Diagnostics, Inc. (PharmaNetics, Inc.)
• Inventors: Oberhardt, Bruce J.
• Primary Examiner(s): Kepplinger, Esther L.
• Assistant Examiner(s): Spiegel, Carol A.
• Application Number:
  US07/192,672
• Time in Patent Office: 1,456 Days
• Field of Search: 435/13, 435/310, 435/805, 435/810, 436/809, 436/46, 436/69, 422/57, 422/58, 422/73, 422/102, 422/110, 422/292, 73/863.71-863.72, 73/864.72
• US Class Current: 435/13
• CPC Class Codes: B01F 21/00 Dissolving separating by dissolving B01D; dissolving to effect cooling F25D5/00
• CPC Class Codes: B01F 2101/23 Mixing of laboratory samples e.g. in preparation of analysing or testing properties of materials
• CPC Class Codes: B01F 23/40 Mixing liquids with liquids; Emulsifying
• CPC Class Codes: B01F 23/56 by introducing solids in liquids, e.g. dispersing or dissolving
• CPC Class Codes: B01F 31/00 Mixers with shaking, oscillating, or vibrating mechanisms
• CPC Class Codes: B01F 31/31 using receptacles with deformable parts, e.g. membranes, to which a motion is imparted
• CPC Class Codes: B01F 33/30 Micromixers
• CPC Class Codes: B01F 35/7172 using capillary forces
• CPC Class Codes: B01L 2200/0647 Handling flowable solids, e.g. microscopic beads, cells, particles
• CPC Class Codes: B01L 2300/0654 Lenses; Optical fibres
• CPC Class Codes: B01L 2300/069 Absorbents; Gels to retain a fluid
• CPC Class Codes: B01L 2300/0822 Slides
• CPC Class Codes: B01L 2300/0825 Test strips
• CPC Class Codes: B01L 2300/0864 comprising only one inlet and multiple receiving wells, e.g. for separation, splitting
• CPC Class Codes: B01L 2300/087 Multiple sequential chambers
• CPC Class Codes: B01L 2300/0887 Laminated structure
• CPC Class Codes: B01L 2300/1827 using resistive heater
• CPC Class Codes: B01L 2300/1861 using radiation
• CPC Class Codes: B01L 2400/0406 capillary forces
• CPC Class Codes: B01L 2400/043 magnetic forces
• CPC Class Codes: B01L 2400/0655 : pinch valves
• CPC Class Codes: B01L 2400/0694 : vents used to stop and induce flow, backpressure valves
• CPC Class Codes: B01L 3/5023 : with a sample being transported to, and subsequently stored in an absorbent for analysis
• CPC Class Codes: B01L 3/5027 : by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip B01L3/5023 takes precedence; micromixers B01F33/30; microreactors for synthesis B01J19/0093; microcapillary devices in general B81B1/00
• CPC Class Codes: G01N 2035/00435 : Refrigerated reagent storage
• CPC Class Codes: G01N 33/4905 : Determining clotting time of blood by chemical methods G01N33/86, C12Q1/56
• CPC Class Codes: G01N 33/525 : Multi-layer analytical elements
• CPC Class Codes: G01N 35/0098 : involving analyte bound to insoluble magnetic carrier, e.g. using magnetic separation magnetic particles used in immunoassays G01N33/54326; magnetic separation in general B03C
• CPC Class Codes: Y10S 435/81 : Packaged device or kit
• CPC Class Codes: Y10S 436/809 : Multifield plates or multicontainer arrays
• CPC Class Codes: Y10T 436/112499 : with sample on test slide

Abstract

A method and apparatus for the measurement of clot formation times, clot dissolution times, or clotting parameters is disclosed. This method performs these measurements by monitoring movement of magnetic particles incorporated in the sample being assayed, where the movement is induced by a magnetic field.

Claims

1. In a coagulation assay comprising combining a coagulation assay reagent and a whole blood sample or plasma sample and obtaining a coagulation assay measurement, the improvement comprising adding to a dry coagulation assay reagent containing magnetic particles distributed substantially homogeneously therethrough, arranged in a substantially flattened format, and under the influence of an oscillating magnetic field or moving permanent magnetic field, or both, a whole blood sample or a plasma sample thereby substantially simultaneously initiating movement of said magnetic particles and the coagulation assay measurement and monitoring movement of said magnetic particles to obtain said assay measurement.

2. A method for performing a clot lysis assay measurement on a whole blood or plasma sample fibrinolytically active containing a component of the blood coagulation cascade system, comprising:

(i) adding a measured amount of said sample to a dry reagent arranged in a substantially flattened configuration and containing a fibrin clot from whole blood or plasma and magnetic particles distributed substantially homogeneously throughout said clot, thereby substantially simultaneously initiating the assay measurement, wherein said reagent containing magnetic particles is subjected to (ia) an oscillating magnetic field or (ib) a moving permanent magnetic field or (ic) a combination of an oscillating magnetic field and a stationary permanent magnetic field; and

(ii) obtaining said assay measurement by monitoring the movement of said magnetic particles induced by (ia), (ib) or (ic).

3. A method for performing a clot lysis assay measurement, comprising:

(i) contacting a whole blood or plasma sample and a dry composition arranged in a substantially flattened configuration and containing at least one whole blood or plasma clot producing reagent and magnetic particles distributed substantially homogeneously throughout said composition to obtain a clot containing magnetic particles;

then

(ii) adding a whole blood or plasma clot lysis assay reagent to said clot, thereby substantially simultaneously initiating said clot lysis assay measurement, and optically monitoring movement in said magnetic particles induced by (ia) an oscillating magnetic field or (ib) a moving permanent magnetic field or (ic) a combination of an oscillating magnetic field and a stationary permanent magnetic field, to obtain said clot lysis assay measurement.

4. A method for performing a clot lysis assay measurement, comprising:

6. The method of claim 4, wherein, either said sample contains a clot lysis assay reagent or said dry composition further contains a clot lysis assay reagent.

8. The method of claim 6, wherein said whole blood or plasma sample contains a clot lysis assay reagent.

10. The method of claim 8, wherein said coagulation assay is a clotting assay.

16. The method of claim 8, wherein said method is carried out in an element for performing said coagulation assay, said method comprising adding said sample to said element, wherein said element comprises a channel structure defining a sample well and a reaction volume in fluid communication with each other, said reaction volume containing said second component, said channel structure having a geometry causing said sample placed in said sample well to be drawn into and filling said reaction volume via capillary action, wherein, after said reaction volume is filled, said sample remains stationary therein.

18. The method of claim 16, further comprising using a means for detecting light scattered or absorbed or reflected from said reaction volume.

20. The method of claim 18, wherein said element is situated between said permanent magnet and said electromagnet.

21. The method of claim 8, wherein (i) said coagulation assay is a clot lysis assay, (ii) said first component is a measured amount of a whole blood or plasma clot dissolving reagent or of a sample containing a whole blood or plasma clot dissolving component, and (iii) said second component is a whole blood or plasma clot containing magnetic particles.

22. The method of claim 20, wherein said clot lysis assay is a tissue plasminogen activator assay.

24. The element of claim 22, wherein said semipermeable layer is a means for monitoring an assay carried out in said reaction volume.

25. The element of claim 22, wherein at least one dry assay reagent is contained within said semipermeable layer.

26. The element of claim 22, said element comprising at least one dry assay reagent layer in contact with a major surface of said semipermeable matrix not affixed to said reflectance layer.

27. The element of claim 25, wherein said dry assay reagent contains at least one enzyme or zymogen of the blood coagulation cascade system.

28. The element of claim 22, wherein said semipermeable matrix is made up of one or more layers of a gel or a membrane, wherein each gel or membrane layer contains at least one dry assay reagent.

29. The element of claim 22, wherein said semipermeable matrix is a layer of gel or a multilayer gel structure or a non-gel membrane with a layer of gel or multilayer gel structure attached thereto.

30. The element of claim 22, wherein said upper surface has attached thereto a plurality of semipermeable reflectance layers, wherein each reflectance layer is separately attached to said upper surface and capable of being utilized as a separate means for monitoring a reaction.

31. The element of claim 22, wherein said semipermeable matrix, or a plurality of said semipermeable matrices, is attached to said upper surface, wherein each semipermeable matrix, or each said plurality of said semipermeable matrices, is capable of being utilized to monitor a reaction.

5. contacting a whole blood or plasma sample and a dry composition arranged in a substantially flattened configuration, containing at least one whole blood or plasma clot producing reagent and magnetic particles distributed substantially homogeneously therethrough, and being subjected to (a) an oscillating magnetic field or (b) a moving permanent magnetic field or (c) a combination of an oscillating magnetic field and a stationary permanent magnetic field, thereby substantially simultaneously initiating movement of said magnetic particles and said clot lysis assay measurement and obtaining the formation of a clot containing magnetic particles, and subsequently allowing lysis of said clot to proceed, thereby obtaining said clot lysis assay measurement by monitoring movement of said magnetic particles.

7. A method for performing a clot lysis assay measurement on a whole blood or plasma sample containing a fibrinolytically active component of the blood coagulation cascade system, comprising:

contacting a whole blood or plasma sample and a fibrin clot arranged in a substantially flattened configuration and containing magnetic particles distributed substantially homogeneously therethrough, said clot being subjected to (a) an oscillating magnetic field or (b) a moving permanent magnetic field or (c) a combination of an oscillating magnetic field and a stationary permanent magnetic field, thereby substantially simultaneously initiating movement of said magnetic particles and the clot lysis assay measurement, and obtaining the clot assay measurement by monitoring movement of said magnetic particles.

9. A method for performing a coagulation assay on a whole blood or plasma sample, comprising:

(i) adding a first, whole blood or plasma, component of the assay to a second component of the assay, wherein said second component comprises a dry coagulation assay reagent arranged in a substantially flattened configuration and containing magnetic particles distributed substantially homogeneously therethrough, and wherein said second is subjected to (ia) an oscillating magnetic field or (ib) a moving permanent magnetic field or (ic) a combination of an oscillating magnetic field and a stationary permanent magnetic field, whereby said adding of said first component to said second component substantially simultaneously initiates movement of said magnetic particles and the coagulation assay measurement; and

(ii) monitoring movement induced in said magnetic particles by (ia) or (ib) or (ic) to obtain said coagulation assay measurement.

11. The method of claim 9, wherein said sample is whole blood.

12. The method of claim 9, wherein said sample is plasma.

13. The method of claim 9, wherein said magnetic particles are induced to move by applying an oscillating magnetic field thereto.

14. The method of claim 9, wherein said magnetic particles are induced to move by applying a moving permanent magnetic field thereto.

15. The method of claim 9, wherein said dry reagent comprises thromboplastin and a calcium salt.

17. The method of claim 15, wherein said element further comprises a means for channeling light from an outside source to said reaction volume.

19. The method of claim 15, wherein said element is disposed in sufficiently close proximity to a permanent magnet and to an electromagnet such that said permanent magnet and said electromagnet provide said combination of an oscillating magnetic field and a stationary permanent magnetic field.

23. An element for performing a liquid sample assay, said element comprising therein a channel structure defining a sample well and a reaction volume in fluid communication with each other, wherein said reaction volume contains at least one dry assay reagent arranged in a substantially flattened configuration and containing magnetic particles distributed substantially homogeneously therethrough, and wherein said reaction volume is defined by an upper surface having attached thereto a reflectance layer comprising a semipermeable matrix, said channel structure having a geometry causing the liquid sample, when placed in said sample well, to be drawn into and filling said reaction volume via capillary action, after said reaction volume is filled said liquid sample remains stationary.

32. A method for performing a coagulation assay measurement, comprising:

(i) adding a whole blood or plasma sample to the sample well of an element comprising;

a channel structure defining a sample well and a reaction volume in fluid communication with each other, wherein said reaction volume is defined by an upper surface having attached thereto a reflectance layer, comprising a semipermeable matrix wherein said reaction volume contains a measured amount of at least one dry coagulation assay reagent arranged in a substantially flattened configuration and containing magnetic particles distributed substantially homogeneously therethrough, wherein a specific volume of said sample is drawn into said reaction volume by capillary action and contacts, together with said semipermeable layer, said reagent to thereby substantially simultaneously initiate said coagulation assay measurement; and

(ii) performing said coagulation assay measurement by measurement the reflectance of said semipermeable layer.

34. The reagent of claim 32, wherein said reagent is thromboplastin or thromboplastin and a calcium salt.

35. The reagent of claim 32, wherein said reagent is a partial thromboplastin time reagent with calcium chloride.

36. The reagent of claim 32, wherein said reagent is a partial thromboplastin reagent with calcium chloride and a clot formation activator.

37. The reagent of claim 32, wherein said reagent is thrombin or a snake venom with thrombotic activity.

38. The reagent of claim 32, wherein said reagent is fibrin, plasminogen and fibrin, a snake venom with thrombin-like activity, or thrombin.

39. The reagent of claim 37, comprising either said snake venom with thrombotic activity or a combination of said snake venom with thrombotic activity and thrombin.

40. The reagent of claim 32, wherein said reagent is a plasminogen assay reagent containing (i) a plasminogen activator and (ii) either fibrin, a snake venom with thrombotic activity, or thrombin.

41. The reagent of claim 39, comprising either said snake venom with thrombotic activity or a combination of said snake venom with thrombotic activity and thrombin.

42. The reagent of claim 32, wherein said reagent is one member selected from the group consisting of streptokinase and urokinase.

43. The reagent of claim 32, wherein said reagent comprises one member selected from the group consisting of natural and synthetic tissue plasminogen activators.

44. The reagent of claim 32, wherein said reagent is an α

-2-antiplasmin assay reagent containing fibrin and plasmin.

45. The dry coagulation assay reagent of claim 32, wherein said reagent comprises:

(4) thrombin or a snake venom with thrombotic activity; and

(8) one member selected from the group consisting of natural and synthetic plasminogen activators.

46. The dry coagulation assay reagent of claim 32, wherein said reagent comprises at least one member selected from the group consisting of streptokinase, tissue plasminogen activator and urokinase.

48. The kit of claim 46, further comprising a transfer pipette.

50. The system of claim 48, further comprising a transfer pipette.

52. The system of claim 48, wherein said instrument further comprises a heating means comprising a resistive heater strip and a thermistor situated in close proximity to said element.

53. The system of claim 48, wherein said element is suitable for performing a whole blood coagulation assay, said channel structure having a geometry causing a blood sample placed in said sample well to be drawn into and filling said reaction volume via capillary action, wherein after said reaction volume is filled, said blood sample remains stationary therein, and wherein said element further comprises an optically or magnetically encodable information means, or both, capable of providing at least one of calibration, quality control, test parameter and patient information.

54. The system of claim 48, wherein said illuminating means includes one or more light sources to illuminate said element and wherein said photometric monitoring means comprises one or more detectors for photometrically monitoring chromogenic or chromomodulating species present in said reaction volume.

56. The system of claim 54, wherein said dry reagent is a blood coagulation promoting reagent.

57. The system of claim 54, comprising a means for controlling the moment transport of said liquid sample from said sample well to said reaction chamber is initiated.

58. The analytical system of claim 54, comprising a plurality of reaction chambers in fluid communication with said sample well, and means for transporting a whole blood or plasma sample from one of said plurality of reaction chambers to another of said plurality of reaction chambers.

33. A dry coagulation assay reagent comprising magnetic particles distributed substantially homogeneously therethrough wherein said reagent is selected from the group consisting of:

(1) one member selected from the group consisting of prothrombin time reagents and (ii) prothrombin time reagents and calcium salts;

(2) partial thromboplastin time reagents with calcium chloride;

(3) partial thromboplastin time reagents with calcium chloride and clot formation activators;

(4) thrombin or a snake venom with thrombotic activity;

(5) fibrin, or plasminogen and fibrin;

(6) plasminogen activator assay reagents containing (i) plasminogen and (ii) either fibrin, a snake venom with thrombotic activity, or thrombin;

(7) plasminogen assay reagents containing (i) a plasminogen activator and (ii) either fibrin, a snake venom with thrombotic activity, or thrombin;

(8) natural and synthetic plasminogen activators;

(9) α

-2-antiplasmin assay reagents containing fibrin and plasmin; and

(10) combinations thereof.

47. A kit for performing a coagulation assay, comprising, in one or more containers, a permanent magnet, a timing means, and an element containing at least one dry coagulation assay reagent arranged in a substantially flattened format and containing magnetic particles distributed substantially homogeneously therethrough.

49. A system for performing a coagulation assay measurement, comprising:

(i) an instrument with a means for temperature control, a means for producing an oscillating magnetic field or for moving a permanent magnetic field, an illuminating means, and a photometric monitoring means; and

(ii) an element for performing said coagulation assay, said element comprising a channel structure defining a sample well and reaction volume in fluid communication with each other, said channel structure having a geometry causing a liquid sample placed in said sample well to be drawn into and filling said reaction volume via capillary action, said reaction volume comprising at least one dry coagulation assay reagent arranged in a substantially flattened configuration and containing magnetic particles distributed substantially homogeneously therethrough.

51. The system of claim 49, wherein said transfer pipette is made of an essentially nonthrombogenic material, comprises a vented end, is capable of being filled with a liquid sample by capillary action, and is capable of expelling said liquid sample by means of pressure after covering or sealing said vented end.

55. A system for performing a coagulation assay, comprising:

(i) a reaction element comprising (1) a sample well for receiving a liquid sample and (2) a reaction chamber containing a dry coagulation assay reagent arranged in a substantially flattened configuration and in which is embedded, substantially homogeneously therethrough, magnetic particles;

(ii) said sample well and said reaction chamber being in fluid communication through a transport zone of geometry such that a volume of liquid sample placed in said sample well and corresponding to the volume of said reaction chamber is transported from said sample well to said reaction chamber simultaneously;

(iii) means for optically monitoring said reaction chamber;

(iv) means for subjecting said reaction chamber to an oscillating magnetic field;

(v) whereby, when said sample is introduced into said reaction chamber, said dry coagulation assay reagent is solubilized and said magnetic particles are thereby freed to move in an oscillating pattern induced by said oscillating magnetic field, thus providing a measurement of the kinetics of said coagulation assay corresponding to changes in the degree of said magnetic particles movement relative to said oscillating magnetic field.

59. A method for performing a coagulation assay, comprising:

(i) subjecting to an oscillating magnetic field a reaction element bearing (1) a sample well for receiving a whole blood or plasma sample and (2) a reaction chamber containing a dry coagulation assay reagent arranged in a substantially flattened format and in which is embedded, substantially homogeneously therethrough, magnetic particles, said sample well and reaction chamber being in fluid communication through a transport zone of geometry such that a volume of sample placed in said sample well and corresponding to the volume of said reaction chamber is transported from said sample well to said reaction chamber simultaneously;

(ii) adding a whole blood or plasma sample susceptible to coagulation to said sample well whereby at least a part of said sample is introduced simultaneously to said reaction chamber, said reagent is solubilized and said particles are freed to move in an oscillating pattern induced by said oscillating magnetic field; and

(iii) optically monitoring said reaction chamber to measure kinetics for the coagulation assay corresponding to changes in the degree of said particle movement relative to said magnetic field.